A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY OF PF-05280586 VERSUS RITUXIMAB FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH CD20-POSITIVE, LOW TUMOR BURDEN, FOLLICULAR LYMPHOMA

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

REPEC

Registry ID

PER-073-14

Enrollment

Registered

2015-05-12

Start date

2015-04-01

Completion date

Unknown

Last updated

2023-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

This is a double blind, randomized, phase 3 clinical trial, (to see complete information go to dossier)

Eligibility

Sex/Gender

All

Age

18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1.Male or female patients aged 18 years or older. 2.Histologically confirmed, Grade 1-3a, untreated, CD20-positive follicular lymphoma (containing no elements of diffuse large B-cell lymphoma). NOTE: Patients can be entered based on a diagnosis of CD20+ follicular lymphoma confirmed at the investigational site. Archival tissue must be sent to the central pathology reviewer for confirmation of diagnosis. Patients must have tissue available for the central pathology review to be enrolled. (see dossier to see information complete)

Exclusion criteria

Exclusion criteria: 1. Patients who are not candidates for rituximab monoterapy (see dossier for complete information)

Countries

Andorra, Brazil, Croatia, Germany, Greece, India, Italy, Japan, Korea South, Mexico, Peru, Philippines, Poland, Portugal, Romania, Russian Federation, South Africa, Spain, Taiwan, Thailand, Turkey, Ukraine, United Kindgdom, United States

Contacts

Public Contactsara flores

PFIZER S.A.

sara.flores@pfizer.com6152004

Outcome results